{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:47:12Z","timestamp":1791841632589,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007681","name":"Florida International University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.obpill.2026.100338","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:08:28Z","timestamp":1790611708000},"page":"100338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3062-7201","authenticated-orcid":false,"given":"Sourav","family":"Das Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-4532","authenticated-orcid":false,"given":"Jaqueline Krystel","family":"Loubeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antara Swarnali","family":"Priyanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajaira A.","family":"Cabrera Tineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Diaz-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-9607","authenticated-orcid":false,"given":"Michelle M.","family":"Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-4200","authenticated-orcid":false,"given":"Mariana","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-2306","authenticated-orcid":false,"given":"Rumi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2026.100338_bib1","series-title":"Prevalence of overweight, obesity, and severe obesity among adults age 20 and older: united States, 1960\u20131962 through August 2021\u2013August 2023 [Internet]","author":"Fryar","year":"2024"},{"issue":"10481","key":"10.1016\/j.obpill.2026.100338_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.obpill.2026.100338_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12519-024-00861-8","article-title":"Global, regional, and national trends in type 2 diabetes mellitus burden among adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis from the global burden of disease study 2021","volume":"21","author":"Xu","year":"2025","journal-title":"World J Pediatr WJP"},{"issue":"10497","key":"10.1016\/j.obpill.2026.100338_bib4","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0140-6736(25)01067-0","article-title":"Managing early-onset type 2 diabetes in the individual and at the population level","volume":"405","author":"Misra","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.obpill.2026.100338_bib5","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1111\/dom.16398","article-title":"Comparative efficacy and tolerability of currently approved incretin mimetics: a systematic analysis of placebo-controlled clinical trials","volume":"27","author":"Kang","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.obpill.2026.100338_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like Peptide-1 receptor agonists for weight loss among adults without diabetes : a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.obpill.2026.100338_bib7","first-page":"2237","article-title":"Real-world effectiveness of tirzepatide versus semaglutide on HbA1c and weight in patients with type 2 diabetes","volume":"16","author":"Hoog","year":"2025","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"23","key":"10.1016\/j.obpill.2026.100338_bib8","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like Peptide-1 receptor agonists to adolescents and young adults, 2020-2023","volume":"331","author":"Lee","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2026.100338_bib10","doi-asserted-by":"crossref","unstructured":"Kildegaard H, Andersen JH, Vinding RK, Kloppenborg JT, Potteg\u00e5rd A. Use of glucagon-like Peptide-1 receptor agonists in Danish adolescents and young adults 2018\u20132025. Obesity. n\/a(n\/a). doi:10.1002\/oby.70234.","DOI":"10.1002\/oby.70234"},{"key":"10.1016\/j.obpill.2026.100338_bib11","series-title":"Investing in the health and well-being of young adults [internet]","author":"Bonnie","year":"2015"},{"issue":"7","key":"10.1016\/j.obpill.2026.100338_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2215-0366(14)00080-7","article-title":"The new life stage of emerging adulthood at ages 18-29 years: implications for mental health","volume":"1","author":"Arnett","year":"2014","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.obpill.2026.100338_bib13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3389\/fpsyt.2019.00864","article-title":"Body dissatisfaction, importance of appearance, and body appreciation in men and women over the lifespan","volume":"10","author":"Quittkat","year":"2019","journal-title":"Front Psychiatr"},{"issue":"12","key":"10.1016\/j.obpill.2026.100338_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3928\/02793695-20230524-02","article-title":"Influence of social media use on body image and well-being among adolescents and young adults: a systematic review","volume":"61","author":"Vincente-Benito","year":"2023","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"5","key":"10.1016\/j.obpill.2026.100338_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/pch\/pxac047","article-title":"A call for action: recommendations to improve transition to adult care for youth with complex health care needs","volume":"27","author":"Toulany","year":"2022","journal-title":"Paediatr Child Health"},{"issue":"10","key":"10.1016\/j.obpill.2026.100338_bib16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jamapediatrics.2025.2308","article-title":"Glucagon-like Peptide-1 receptor agonist eligibility among US adolescents and young adults","volume":"179","author":"Chetty","year":"2025","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.obpill.2026.100338_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.16951","article-title":"Patient experiences with GLP-1 receptor agonists","volume":"9","author":"de Vere Hunt","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.obpill.2026.100338_bib18","doi-asserted-by":"crossref","unstructured":"Ibsen CK, Brostr\u00f8m Kousgaard M, Olsen S, Christiansen AKL, Sandholdt CT, R\u00f8rth R, et al. Patients' experiences with GLP1-RAs \u2013 a systematic review. Scand J Prim Health Care. 43(2):370\u2013379. doi:10.1080\/02813432.2025.2477141 PubMed PMID: 40071612; PubMed Central PMCID: PMC12090293.","DOI":"10.1080\/02813432.2025.2477141"},{"issue":"1","key":"10.1016\/j.obpill.2026.100338_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70069","article-title":"\u201cThis Is My Decision\u201d: a Qualitative Study of Individuals' perspectives on use of semaglutide for weight loss","volume":"137","author":"Graab\u00e6k","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.obpill.2026.100338_bib20","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1111\/dom.16405","article-title":"GLP-1 medication and weight loss: barriers and motivators among 1659 participants managed in a virtual setting","volume":"27","author":"Naveed","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.obpill.2026.100338_bib21","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1111\/dom.70599","article-title":"Pre-treatment concerns and their association with functioning and well-being during incretin-based therapy: a cross-sectional study","volume":"28","author":"Kapan","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.obpill.2026.100338_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70227","article-title":"Documentation of compounded GLP-1 receptor agonists in a large primary care dataset","volume":"34","author":"Hendrix","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"10.1016\/j.obpill.2026.100338_bib23","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1001\/jama.2025.15841","article-title":"Medicare part D coverage and costs for glucagon-like Peptide-1 receptor agonists","volume":"334","author":"Klebanoff","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.obpill.2026.100338_bib24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMp2312816","article-title":"Direct-to-Consumer platforms for new antiobesity medications - concerns and potential opportunities","volume":"390","author":"Golovaty","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.obpill.2026.100338_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jadohealth.2026.03.017","article-title":"Weight loss medications in youth: decision-making experiences, eating behaviors, and uncertainty about endpoint","volume":"79","author":"Nehushtan","year":"2026","journal-title":"J Adolesc Health Off Publ Soc Adolesc Med"},{"issue":"2","key":"10.1016\/j.obpill.2026.100338_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/109019818801500203","article-title":"Social learning theory and the health belief model","volume":"15","author":"Rosenstock","year":"1988","journal-title":"Health Educ Q"},{"issue":"1","key":"10.1016\/j.obpill.2026.100338_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","article-title":"Revisiting the behavioral model and access to medical care: does it matter?","volume":"36","author":"Andersen","year":"1995","journal-title":"J Health Soc Behav"},{"key":"10.1016\/j.obpill.2026.100338_bib28","series-title":"A hybrid approach to thematic analysis in qualitative research: using a practical example [Internet]","author":"Swain","year":"2018"},{"key":"10.1016\/j.obpill.2026.100338_bib29","series-title":"Qualitative inquiry and research design: choosing among five approaches","first-page":"448","author":"Creswell","year":"2013"},{"issue":"3","key":"10.1016\/j.obpill.2026.100338_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12666","article-title":"Managing the new wave of weight loss medication in general practice: a qualitative study","volume":"14","author":"Andreassen","year":"2024","journal-title":"Clin Obes"},{"issue":"9","key":"10.1016\/j.obpill.2026.100338_bib31","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1007\/s00464-025-11938-4","article-title":"Evaluation of social media videos on weight-loss surgery and GLP-1 agonists: a content quality and reliability analysis","volume":"39","author":"Lee","year":"2025","journal-title":"Surg Endosc"},{"issue":"1","key":"10.1016\/j.obpill.2026.100338_bib32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00210-025-04403-5","article-title":"Misrepresentation of semaglutide in social media","volume":"399","author":"Propfe","year":"2026","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"8","key":"10.1016\/j.obpill.2026.100338_bib33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.7326\/ANNALS-25-02714","article-title":"Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline from the American college of physicians (April 2026)","volume":"179","author":"Qaseem","year":"2026","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.obpill.2026.100338_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10865-019-00131-3","article-title":"Association of social network factors with weight status and weight loss intentions among hispanic adults","volume":"43","author":"Wieland","year":"2020","journal-title":"J Behav Med"},{"issue":"4","key":"10.1016\/j.obpill.2026.100338_bib35","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-2955","article-title":"Intergenerational transmission of parent encouragement to diet from adolescence into adulthood","volume":"141","author":"Berge","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.obpill.2026.100338_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17437199.2011.569936","article-title":"The impact of familism on physical and mental health among hispanics in the United States","volume":"8","author":"Katiria Perez","year":"2014","journal-title":"Health Psychol Rev"},{"issue":"2","key":"10.1016\/j.obpill.2026.100338_bib37","article-title":"Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study","volume":"4","author":"Mattingly","year":"2026","journal-title":"Health Aff Sch"},{"issue":"4","key":"10.1016\/j.obpill.2026.100338_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2352-4642(24)00354-7","article-title":"Weight-loss medications: promoting health and not harm","volume":"9","author":"Hartman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"8","key":"10.1016\/j.obpill.2026.100338_bib39","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf084","article-title":"Global rise of compounded weight-loss medicines: a worrisome trend","volume":"9","author":"Sood","year":"2025","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.obpill.2026.100338_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.28280","article-title":"Safety and risk assessment of No-Prescription online semaglutide purchases","volume":"7","author":"Ashraf","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.obpill.2026.100338_bib41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World health organization guideline on the use and indications of glucagon-like Peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2026.100338_bib42","article-title":"Rising costs cited by 68% of GLP-1 users as a major treatment barrier","author":"Steinzor","year":"2026","journal-title":"AJMC [Internet]"},{"issue":"1","key":"10.1016\/j.obpill.2026.100338_bib43","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American college of lifestyle medicine, the American society for nutrition, the obesity medicine association, and the obesity society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.obpill.2026.100338_bib44","unstructured":"Centers for Medicare & Medicaid Services. Centers for Medicare & Medicaid Services [Internet]. [cited 2026 August 14]. Medicare GLP-1 bridge | CMS. Available from: https:\/\/www.cms.gov\/medicare\/coverage\/prescription-drug-coverage\/medicare-glp-1-bridge."},{"key":"10.1016\/j.obpill.2026.100338_bib45","unstructured":"Original medicare (part A and B) eligibility and enrollment | CMS [Internet]. [cited 2026 August 25]. Available from: https:\/\/www.cms.gov\/medicare\/enrollment-renewal\/original-part-a-b."},{"key":"10.1016\/j.obpill.2026.100338_bib46","doi-asserted-by":"crossref","unstructured":"Pearson SD, Whaley CM, Emond SK. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. J Comp Eff Res. 14(9):e250083. doi:10.57264\/cer-2025-0083 PubMed PMID: 40641455; PubMed Central PMCID: PMC12403326.","DOI":"10.57264\/cer-2025-0083"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266736812600094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266736812600094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:09:19Z","timestamp":1791839359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266736812600094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S266736812600094X"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100338","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100338"}}